FoundationOne CDx assay available in U.S.
April 17, 2018—Foundation Medicine announced that its FoundationOne CDx, an FDA-approved comprehensive genomic profiling assay for all solid …
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Sakura launches Tissue-Tek Prisma Plus
April 13, 2018—Sakura Finetek USA launched its Tissue-Tek Prisma Plus Automated Slide Stainer, a second-generation Prisma platform with a throughput of 530 slides per hour. “Like its predecessor, the Tissue-Tek Prisma Automated Slide Stainer, with several thousand units installed worldwide, Tissue-Tek Prisma Plus continues to be the slide stainer of choice for large commercial laboratories and hospitals,” George R. Kennedy, SVP of sales and marketing at Sakura Finetek USA, said in a press release. “We are proud of the performance
Beckman introduces Access Sensitive Estradiol
April 11, 2018—Beckman Coulter Diagnostics announced the launch of its Access Sensitive Estradiol assay in the U.S. and in a majority of markets worldwide. The test is commonly ordered for detecting estradiol levels in women, children, and men. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions. It has a broad measuring range, surpassing clinical decision limits for in vitro fertilization hyper responders. This may allow laboratories to report accurate patient
DiaSorin gets FDA clearance for PCT assay
April 6, 2018—DiaSorin received clearance from the Food and Drug Administration to market the Liaison Brahms PCT II Gen assay for the quantitative determination of procalcitonin. “I am pleased to announce the addition of the Brahms PCT II Gen assay to our growing specialty menu in the U.S. market”, John Walter, president of DiaSorin, said in a statement. “I’m proud of the great collaboration between various DiaSorin groups that allowed for the rapid clearance of the product. In addition to
AdvantEdge acquires PMI
April 5, 2018—AdvantEdge Healthcare Solutions, a medical billing company, has acquired Professional Management Inc., a Baltimore-based medical …
FDA authorizes DexcomG6 CGM system
March 30, 2018—The FDA has granted a de novo request to Dexcom for its Dexcom G6 integrated continuous glucose monitoring system for determining blood glucose levels for people with diabetes ages two and up. This is the first type of CGM system permitted by the agency to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters, or other electronic devices used
Roche launches digital pathology slide scanner
March 28, 2018—Roche launched the Ventana DP 200 high-speed slide scanner for digital pathology. The scanner features a tray-based design that enables no-touch slide processing for reduced workflow and a scan speed of less than 49 seconds for a 15-by-15 millimeter scan area. It is Digital Imaging and Communications in Medicine (DICOM) standard compatible and integrates with image management servers, including Ventana Virtuoso software. “The Ventana DP 200 slide scanner provides the pathology lab with image quality and ease of
CAP TODAY webinar on BRCA mutation testing
March 26, 2018—CAP TODAY is hosting a webinar titled “Developing Perspectives on BRCA Testing: New Horizons for Breast Cancer” on Thursday, March 29, 1:30 PM ET. Tabetha Sundin, PhD, HCLD(ABB), MB(ASCP)CM, and Leigha Senter-Jamieson, MS, LGC, will discuss the rationale for BRCA mutation testing in breast cancer, the key highlights of the BRCA testing and interpretation process, and reconsidering multidisciplinary team roles and responsibilities to streamline the testing experience. This hourlong webinar will be moderated by CAP TODAY publisher Bob
Webinar: NGS in NSCLC biomarker testing
March 23, 2018—CAP TODAY is hosting a webinar titled “Endeavor to leave no patient behind: next-generation sequencing (NGS) in routine NSCLC biomarker testing” on Wednesday, March 28, 1 PM ET. Boaz Kurtis, MD, medical director of Cancer Genetics, Inc., will discuss how to practice precision oncology based on fast-changing guidelines and to ensure even challenging samples get tested to achieve best outcomes for as many NSCLC patients as possible. Dr. Kurtis will present Cancer Genetics’ testing model, case studies, and lessons learned
Cytocell unveils new website
March 20, 2018—Oxford Gene Technology has redeveloped its Cytocell fluorescence in situ hybridization probes website, www.cytocell.com …